Endonovo Therapeutics, Inc. engages in developing off bio-electronic approach to regenerative medicine. It focuses on rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. The company was founded on May 26, 2011 and is headquartered in Woodland Hills, CA.
Company profile
Ticker
ENDV
Exchange
Website
CEO
Alan Brian Collier
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
Former names
Hanover Portfolio Acquisitions, Inc.
SEC CIK
ENDV stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
2 Feb 24
8-K
Entry into a Material Definitive Agreement
3 Jan 24
10-Q
2023 Q3
Quarterly report
28 Dec 23
8-K
Entry into a Material Definitive Agreement
4 Dec 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
8-K
Other Events
12 Oct 23
1-A/A
Offering $5.00 mm in Equity
25 Aug 23
10-Q
2023 Q2
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
Latest ownership filings
4
Alan Brian Collier
7 Jul 20
4
Alan Brian Collier
26 Feb 20
4/A
Alan Brian Collier
24 Jan 20
4/A
Alan Brian Collier
24 Jan 20
4
Alan Brian Collier
23 Jan 20
4
Alan Brian Collier
31 Dec 19
4
Alan Brian Collier
9 Dec 19
4
Alan Brian Collier
26 Nov 19
4
Alan Brian Collier
15 Nov 19
4
Alan Brian Collier
4 Nov 19
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | ||||||
Cash burn (monthly) | 10.87 k | 1.93 k | 255.39 k | 367.01 k | 21.79 k | 52.49 k |
Cash used (since last report) | 64.92 k | 11.52 k | 1.53 mm | 2.19 mm | 130.16 k | 313.58 k |
Cash remaining | -64.92 k | -11.52 k | -1.53 mm | -2.19 mm | -130.16 k | -313.58 k |
Runway (months of cash) | -6.0 | -6.0 | -6.0 | -6.0 | -6.0 | -6.0 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|